Why the study?
Does apixaban reduce the risk of stroke or systemic embolism in patients with atrial fibrillation for whom vitamin K antagonist therapy is unsuitable?
Does apixaban reduce the risk of stroke or systemic embolism in patients with atrial fibrillation for whom vitamin K antagonist therapy is unsuitable?
Apixaban effectively reduces the risk of stroke or systemic embolism without significantly increasing major bleeding in atrial fibrillation patients unsuitable for vitamin K antagonists.
No takes yet. Share an insight, caveat, or question.
Supports apixaban over aspirin for AF patients unsuitable for VKA; extends randomized evidence for stroke prevention without excess bleeding.
Connolly et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: